Global PCSK9 Inhibitors Market Overview
PCSK9 inhibitors are an example of a key challenge in modern medicine: a promising new treatment that is also very costly. Mutations in the PCSK9 gene were linked to low levels of low-density lipoprotein cholesterol in a sample of a French kinship (LDL-C). The low-density lipoprotein (LDL) receptor-mediated cholesterol metabolism is regulated by the proprotein convertase subtilisin/kexin type 9 (PCSK9). Several drug classes targeting the PCSK9 pathway are currently being developed; monoclonal antibodies targeting PCSK9 were the first to be accepted. Evolocumab and alirocumab are two drugs that have been approved for use in people with atherosclerotic cardiovascular disease or hereditary hypercholesterolemia who haven't seen enough improvement with maximally tolerated statin therapy. Despite the fact that early PCSK9 inhibitor trials were underpowered to track their effects on hard clinical results, a meta-analysis found a 50% reduction in cardiovascular events. The global PCSK9 inhibitors market accounted for US$ x.x billion in 2020 and is estimated to be US$ x.x billion by 2030 and is anticipated to register a CAGR of x.x% .
Impact of Covid-19 pandemic on market
Several pathophysiological pathways of coronavirus disease are disrupted by inhibitors of the proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 inhibitors have been shown to help patients with pneumonia and sepsis in human trials. This drug can act as immunomodulator in covid-19, preventing serious complications including acute respiratory distress syndrome and cytokinesis release syndrome.
Global PCSK9 Inhibitors Market Dynamics
Growth in business operations by emerging and small sized players
During the forecast period, the global PCSK9 Inhibitors market was valued at a significant pace. The market was increasing steadily in 2020, and with key players adopting more strategies, the market is expected to increase over the forecasted horizon. New drugs' immunogenicity, on the other hand, may play a critical role in their efficacy. Following the outcome of SPIRE-1,2, Bococizumab's was discontinued from the market. PCSK9 inhibitors have tremendous potential, as evidenced by their inclusion (as a new class of drugs that lower LDL cholesterol concentration) in the New Lipid Guidelines published in Rome in 2016. Drug research efforts have focused on finding ways to block PCSK9 at various stages. Silencing messenger RNA (mRNA of PCSK9), for example, is a novel way to combat hypercholesterolemia.
Global PCSK9 Inhibitors Market Segmentation
Source: Prophecy Market Insights |Disclaimer: Data is only a representation. Actual data may vary in the final report.
Source: Prophecy Market Insights
The PCSK9 inhibitors market is segmented based on type, application, and region.
On the basis of type, the PCSK9 inhibitors market is segmented into, Repatha (Evolocumab), Praluent (Alirocumab), Others (Pipeline drugs)). On the basis of application, the target market is segmented into Drug Development, Clinical Application and Others. On the basis of region , the market is segmented into North America, Europe, Asia Pacific , Latin America, and Middle East Africa.
Regional Insights:
On region, the PCSK9 inhibitors market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. PCSK9 inhibitors are over 100 times more expensive than statins in the U.S. market, and only a small portion of their higher cost can ever be recouped by preventing cardiovascular problems, particularly in lower-risk patients. PCSK9 inhibitors' financial effect can be minimised by limiting their use to the highest-risk patients who can benefit the most clinically.
Report Scope:
|
Attribute |
Details |
|
Base year for estimation |
2020 |
|
Forecast period |
2020 – 2030 |
|
Market representation |
Revenue in USD Million & CAGR from 2020 – 2030 |
|
Market Segmentation |
By type- Repatha (Evolocumab), Praluent (Alirocumab), Others (Pipeline drugs) By Application– Drug Development, Clinical Application and Others By region- North America, Europe, Asia Pacific, Latin America, Middle east and Africa |
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
|
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the PCSK9 inhibitors market report based on type, application, and region.
PCSK9 inhibitors Market, By Region:
-
-
- North America
-
- U.S.
- Canada
-
- Europe
-
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
-
- Asia Pacific
-
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
-
- Latin America
-
- Brazil
- Mexico
- Rest of Latin America
-
- Middle East & Africa
-
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
-
- North America
-
Global PCSK9 Inhibitors Market Key Players
The key players operating in the Main PCSK9 inhibitors market include Amgen, Sanofi, Eli lilly, Merck, Affiris, Novartis, Roche, Astra Zeneca, BMS, Daichi Sankyo, Cyon therapeutics, and Ionia Pharmaceuticals.
Global PCSK9 Inhibitors Market Company Profile
- Amgen
- Alnylam
- Pfizer
- EliLilly
- Merck
- Sanofi
- Affiris
- Roche
- Novartis
- AstraZeneca
- BMS
- DaichiSankyo
- Ionispharmaceuticals
- CyonTherapeutics
-
“*” marked represents similar segmentation in other categories in the respective section
Global PCSK9 Inhibitors Market Table of Contents
- Research Objective and Assumption
- Preface
- Research Objectives
- Study Scope
- Years Considered for the study
- Assumptions
- Abbreviations
- Research Methodology
- Research data
- Primary Data
- Primary Interviews
- Primary Breakdown
- Key data from Primary Sources
- Key Thickness Insights
- Secondary Data
- Major Secondary Sources
- Secondary Sources
- Market Estimation
- Top-Down Approach
- Approach for estimating Market Share by Top-Down Analysis (Supply Side)
- Bottom-Up Approach
- Approach for estimating market share by Bottom-up Analysis (Demand Side)
- Market Breakdown and Data Triangulation
- Research Assumptions
- Market Purview
- Executive Summary
- Key Findings—Global Outlook for PCSK9 Inhibitor Strategies
- Key Questions this Study will Answer
- Market Snippet, By Type
- Market Snippet, By Application
- Market Snippet, By Region
- Opportunity Map Analysis
- Executive Summary—3 Big Predictions
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- DR Impact Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Opportunity Orbit
- Market Investment Feasibility Index
- Macroeconomic Factor Analysis
- Market Dynamics
- Global PCSK9 Inhibitor Market, By Type, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Bococizumab
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Repatha (Evolocumab)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Praluent (Alirocumab)
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Other
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global PCSK9 Inhibitor Market, By Application, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Segment Trends
- Drug Development
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Clinical Application
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Others
- Overview
- Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2030
- Overview
- Global PCSK9 Inhibitor Market, By Region, 2020 – 2030, (US$ Mn)
- Overview
- Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2030
- Y-o-Y Growth Analysis (%), 2020 – 2030
- Regional Trends
- North America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- U.S.
- Canada
- Europe
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- UK
- France
- Germany
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- India
- Japan
- South Korea
- China
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Market Size and Forecast (US$ Mn), By Type, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Application, 2020 – 2030
- Market Size and Forecast (US$ Mn), By Country, 2020 – 2030
- GCC
- Israel
- South Africa
- Rest of Middle East
- Overview
- Competitive Landscape
- Heat Map Analysis
- Market Presence and Specificity Analysis
- Company Profiles
- Amgen
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- Alnylam
- Pfizer
- EliLilly
- Merck
- Sanofi
- Affiris
- Roche
- Novartis
- AstraZeneca
- BMS
- DaichiSankyo
- Ionispharmaceuticals
- CyonTherapeutics
The Last Word
-
- Future Impact
- About Us
- Contact
FAQs
The PCSK9 inhibitors market is segmented based on type, application, and region.
The market was increasing steadily in 2020, and with key players like amgen, Affiris, novartis and others adopting more strategies, the market is expected to increase over the forecasted horizon.
United states is expected to lead the market. PCSK9 inhibitors are over 100 times more expensive than statins on the market in the United States, and only a small portion of their higher cost can ever be recouped by preventing cardiovascular problems, particularly in lower-risk patients.
The key players operating in the Main PCSK9 inhibitors market includes Amgen, Sanofi, Eli lilly, Merck, Affiris, Novartis, Roche, Astra Zeneca, BMS, Daichi sankyo, Cyon therapeutics, and Ionia Pharmaceuticals.